 |
11 Diseases |  |
24 Trials |
|
24 Trials |  |
1081 News |  |
| «12...234567891011121314 |
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
New P3 trial: SOURCE: Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma (clinicaltrials.gov) - Jan 23, 2018
P3, N=140, Not yet recruiting, Sponsor: AstraZeneca
- |||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Enrollment open: NAVIGATOR: Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma (clinicaltrials.gov) - Dec 4, 2017
P3, N=1060, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting
- |||||||||| Tezspire (tezepelumab) / AstraZeneca, Amgen
Clinical: NAVIGATOR: Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma (clinicaltrials.gov) - Nov 20, 2017
P3, N=1060, Not yet recruiting, Sponsor: AstraZeneca
- ||| Tezspire (tezepelumab) / AstraZeneca, Amgen
Clinical: PATHWAY: Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma (clinicaltrials.gov) - Oct 12, 2017
P2, N=584, Completed, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting N=955 --> 584
- |||| Tezspire (tezepelumab) / AstraZeneca, Amgen
Clinical: PATHWAY: Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma (clinicaltrials.gov) - Apr 14, 2017
P2, N=955, Completed, Sponsor: MedImmune LLC
N=955 --> 584 Active, not recruiting --> Completed
- | Tezspire (tezepelumab) / AstraZeneca, Amgen
Clinical: Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy (clinicaltrials.gov) - Mar 21, 2017
P1/2, N=120, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> Feb 2019
- ||| Tezspire (tezepelumab) / AstraZeneca, Amgen
Clinical: PATHWAY: Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma (clinicaltrials.gov) - Jan 10, 2017
P2, N=955, Active, not recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> Feb 2019 N=552 --> 955
- Tezspire (tezepelumab) / AstraZeneca, Amgen
Clinical: Effects of Anti-TSLP in Patients With Asthma (clinicaltrials.gov) - Jan 4, 2017
P2, N=40, Recruiting, Sponsor: Celeste Porsbjerg
N=552 --> 955 Not yet recruiting --> Recruiting | Initiation date: Apr 2016 --> Aug 2016 | Trial primary completion date: Dec 2017 --> Dec 2018
- |||| Tezspire (tezepelumab) / AstraZeneca, Amgen
P2 data, P2a data: ALLEVIAD: Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis (clinicaltrials.gov) - Sep 20, 2016
P2a, N=155, Completed, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting | Initiation date: Apr 2016 --> Aug 2016 | Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed
- Tezspire (tezepelumab) / AstraZeneca, Amgen
Clinical: Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy (clinicaltrials.gov) - Aug 31, 2016
P1/2, N=120, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Trial primary completion date: Jul 2016 --> Feb 2017
- | Tezspire (tezepelumab) / AstraZeneca, Amgen
Clinical: A Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma (clinicaltrials.gov) - Jul 11, 2016
P1, N=26, Completed, Sponsor: MedImmune LLC
Trial primary completion date: Jul 2016 --> Feb 2017 Active, not recruiting --> Completed
- ||| Tezspire (tezepelumab) / AstraZeneca, Amgen
P2 data, P2a data: ALLEVIAD: Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis (clinicaltrials.gov) - Jul 5, 2016
P2a, N=155, Active, not recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Phase classification: P2 --> P2a | N=100 --> 155
- Tezspire (tezepelumab) / AstraZeneca, Amgen
Clinical: A Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma (clinicaltrials.gov) - Apr 21, 2016
P1, N=22, Active, not recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting | Phase classification: P2 --> P2a | N=100 --> 155 Recruiting --> Active, not recruiting
- Tezspire (tezepelumab) / AstraZeneca, Amgen
Clinical: Effects of Anti-TSLP in Patients With Asthma (clinicaltrials.gov) - Mar 4, 2016
P2, N=40, Not yet recruiting, Sponsor: Celeste Porsbjerg
- ||| Tezspire (tezepelumab) / AstraZeneca, Amgen
Clinical: PATHWAY: Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma (clinicaltrials.gov) - Nov 5, 2015
P2, N=552, Active, not recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Dec 2016
- Tezspire (tezepelumab) / AstraZeneca, Amgen
Clinical: A Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma (clinicaltrials.gov) - Oct 22, 2015
P1, N=22, Recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Dec 2016 Not yet recruiting --> Recruiting
- |||| Tezspire (tezepelumab) / AstraZeneca, Amgen
P2 data, P2a data: ALLEVIAD: Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis (clinicaltrials.gov) - Oct 6, 2015
P2, N=100, Recruiting, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Tezspire (tezepelumab) / AstraZeneca, Amgen
P2 data, P2a data: ALLEVIAD: Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis (clinicaltrials.gov) - Aug 17, 2015
P2, N=100, Not yet recruiting, Sponsor: MedImmune LLC
- | Tezspire (tezepelumab) / AstraZeneca, Amgen
Clinical: A Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma (clinicaltrials.gov) - Jul 31, 2015
P1, N=22, Not yet recruiting, Sponsor: MedImmune LLC
- Tezspire (tezepelumab) / AstraZeneca, Amgen
Clinical: Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=120, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2017 --> Jul 2016
- Tezspire (tezepelumab) / AstraZeneca, Amgen
Clinical: Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy (clinicaltrials.gov) - Dec 10, 2014
P1/2, N=120, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Oct 2017 --> Jul 2016 Not yet recruiting --> Recruiting
- ||| Tezspire (tezepelumab) / AstraZeneca, Amgen
Clinical: PATHWAY: Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma (clinicaltrials.gov) - Nov 25, 2014
P2, N=552, Recruiting, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting N=1383 --> 552 | Trial primary completion date: Oct 2016 --> Jul 2016
- | Tezspire (tezepelumab) / AstraZeneca, Amgen
Clinical: Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy (clinicaltrials.gov) - Sep 11, 2014
P1/2, N=120, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- || Tezspire (tezepelumab) / AstraZeneca, Amgen
Clinical: PATHWAY: Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma (clinicaltrials.gov) - May 12, 2014
P2, N=1383, Recruiting, Sponsor: MedImmune LLC
N=1383 --> 552 | Trial primary completion date: Oct 2016 --> Jul 2016 Trial primary completion date: Jul 2016 --> Oct 2016
- || Tezspire (tezepelumab) / AstraZeneca, Amgen
Clinical: PATHWAY: Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma (clinicaltrials.gov) - May 12, 2014
P2, N=1383, Recruiting, Sponsor: MedImmune LLC
Trial primary completion date: Jul 2016 --> Oct 2016 Trial completion date: Sep 2016 --> Dec 2016
- |||| Tezspire (tezepelumab) / AstraZeneca, Amgen
Clinical: PATHWAY: Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma (clinicaltrials.gov) - May 12, 2014
P2, N=1383, Recruiting, Sponsor: MedImmune LLC
Trial completion date: Sep 2016 --> Dec 2016 Not yet recruiting --> Recruiting
- || Tezspire (tezepelumab) / AstraZeneca, Amgen
P1 data: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Single Administration in Healthy Male Japanese Subjects (clinicaltrials.gov) - Feb 10, 2014
P1, N=64, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting N=24 --> 64
- ||| Tezspire (tezepelumab) / AstraZeneca, Amgen
P1 data: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Single Administration in Healthy Male Japanese Subjects (clinicaltrials.gov) - Feb 10, 2014
P1, N=64, Completed, Sponsor: AstraZeneca
N=24 --> 64 Recruiting --> Completed
- ||||| Tezspire (tezepelumab) / AstraZeneca, Amgen
Clinical: PATHWAY: Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma (clinicaltrials.gov) - Feb 2, 2014
P2, N=1383, Not yet recruiting, Sponsor: MedImmune LLC
- | Tezspire (tezepelumab) / AstraZeneca, Amgen
Clinical: Double-blind, Multiple Dose Study in Subjects With Mild Atopic Asthma (clinicaltrials.gov) - Sep 15, 2013
P1, N=31, Completed, Sponsor: Amgen
Recruiting --> Completed Recruiting --> Completed
- ||| Tezspire (tezepelumab) / AstraZeneca, Amgen
P1 data: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Single Administration in Healthy Male Japanese Subjects (clinicaltrials.gov) - Jul 29, 2013
P1, N=64, Completed, Sponsor: AstraZeneca